The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute coronary syndromes (ACS) without ST-segment elevation require effective antiplatelet therapy.
• Clopidogrel is an antiplatelet medication used in managing ACS.
• Treatment strategies for ACS vary, including conservative and aggressive approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of clopidogrel in patients with ACS without ST-segment elevation.
• To assess the impact of clopidogrel on major adverse cardiovascular events and bleeding.

Main Methods:

• A large, randomized, placebo-controlled trial was conducted.
• Participants presented with acute coronary syndromes without ST-segment elevation.
• The study was performed in centers employing a conservative management approach.

Main Results:

• Clopidogrel significantly decreased the combined endpoint of cardiovascular death, nonfatal myocardial infarction, or stroke by 20%.
• An increase in bleeding events was observed in the clopidogrel group compared to placebo.
• The observed benefits and risks may differ in centers with aggressive early angiography and revascularization strategies.

Conclusions:

• Clopidogrel demonstrates significant efficacy in reducing major adverse cardiovascular events for ACS patients without ST-segment elevation.
• The increased bleeding risk associated with clopidogrel necessitates careful consideration of patient selection and treatment context.
• Treatment strategies involving clopidogrel may require individualization, particularly in centers utilizing early invasive interventions.